Cincinnati Business Courier: Cincinnati Children’s lands third largest grant ever
UC faculty partner with Cincinnati Children's
Cincinnati Business Courier reports that Cincinnati Children’s has landed $28 million in federal funding – the hospital's third-largest single grant ever – to establish a data management and coordinating center for an agency that oversees researchers seeking cures for hundreds of rare diseases.
The five-year grant from the National Center for Advancing Translational Sciences, one of the National Institutes of Health, will fund a coordinating center to facilitate studies involving thousands of scientists across the United States and 22 other nations.
The center based at the hospital in Avondale will collect, organize, share and analyze big data about rare diseases that are often disabling or fatal. The data management and coordinating center will be led by three senior Children’s scientists and University of Cincinnati College of Medicine faculty members. They include Eileen King and Dr. Maurizio Macaluso, both professors in the UC Department of Pediatrics, and Peter White, professor and chair of the UC Department of Biomedical Informatics.
Read the Business Courier Story online
Learn more about how University of Cincinnati faculty will also support this work.
Photo courtesy of Cincinnati Children's
Related Stories
UC Board of Trustees approves $12 million for building design phase for new welcome gateway
March 13, 2026
The UC Board of Trustees approved $12 million at its Feb. 24 meeting for the design phase of a new Welcome Gateway Building for Uptown campus.
Breakthrough skin science discovery
March 12, 2026
A research collaboration between the University of Cincinnati and global cosmetics company Kose led to the creation of a novel anti aging spot fading serum.
Study: Additional radiation for liver cancer does not increase toxicity
March 10, 2026
New research led by University of Cincinnati Cancer Center researchers published in the American Journal of Clinical Oncology found external beam radiation therapy (EBRT) is safe to administer to patients with liver cancer even after they undergo a targeted internal radiation therapy called Y90.